Glucocorticoid receptor blockade as disease-modifying treatment for depression with childhood trauma: a study protocol of the RESET-medication study

被引：0
|
作者：
Linsen, F. [1 ]
Verhoeven, J. [1 ]
Bet, P. [1 ]
Penninx, B. [1 ]
Meijer, O. [2 ]
Vinkers, C. [1 ]
机构：
[1] Amsterdam UMC Locat VUmc, Dept Psychiat, Amsterdam, Netherlands
[2] Leiden UMC, Dept Med, Div Endocrinol, Leiden, Netherlands
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2021年 / 53卷
关键词：
D O I：
10.1016/j.euroneuro.2021.10.772
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.0700
引用
收藏
页码：S513 / S513
页数：1
相关论文
共 50 条
  • [11] Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study
    Ghezzi, A
    Amato, MP
    Capobianco, M
    Gallo, P
    Marrosu, G
    Martinelli, V
    Milani, N
    Milanese, C
    Moiola, L
    Patti, F
    Pilato, V
    Pozzilli, C
    Trojano, M
    Zaffaroni, M
    Comi, G
    MULTIPLE SCLEROSIS JOURNAL, 2005, 11 (04) : 420 - 424
  • [12] Eligibility for disease-modifying treatment in Alzheimer's disease: Evidence from an observational study over 4 years
    Caratozzolo, Salvatore
    Rozzini, Luca
    Cosseddu, Maura
    Turrone, Rosanna
    Compostella, Silvia
    Benussi, Alberto
    Scalvini, Andrea
    Zoppi, Nicola
    Giunta, Marcello
    Barbara, Paghera
    Padovani, Alessandro
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 89 - 89
  • [13] Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of the ITEMS (Immunomodulatory Treatment of Early-onset MS) study group
    Ghezzi, A
    Amato, MP
    Gallo, P
    Marrosu, MG
    Martinelli, V
    Milani, N
    Milanese, C
    Moiola, L
    Patti, F
    Pozzilli, C
    Trojano, M
    Zaffaroni, M
    Pilato, V
    Comi, G
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S234 - S234
  • [14] Effect of disease-modifying treatment on spinal cord lesion formation in multiple sclerosis: A retrospective observational study
    Kreiter, Daniel
    Spee, Romy
    Merry, Audrey
    Hupperts, Raymond
    Gerlach, Oliver
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 79
  • [15] Clinical management and disease-modifying treatment for amyotrophic lateral sclerosis in African hospital centers: the TROPALS study
    Luna, Jaime
    Jost, Jeremy
    Diagana, Mouhamadou
    Aissa, Leila Ait
    Tazir, Meriem
    Pacha, Lamia Ali
    Kacem, Imen
    Gouider, Riadh
    Henning, Franclo
    Basse, Anna
    Cisse, Ousmane
    Balogou, Aa Koffi
    Kombate, Damelan
    Agbetou, Mendinatou
    Houinato, Dismand
    Gnonlonfoun, Dieu Donne
    Millogo, Athanase
    Agba, Thierry
    Belo, Mouftao
    Sengxeu, Noudy
    Hamidou, Bello
    Preux, Pierre-Marie
    Benoit, Marin
    Couratier, Philippe
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2022, 23 (3-4) : 279 - 283
  • [16] Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol
    Vormfelde, Stefan Viktor
    Ortler, Sonja
    Ziemssen, Tjalf
    JMIR RESEARCH PROTOCOLS, 2016, 5 (01):
  • [17] Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study
    Genovese, Mark C.
    McKay, James D.
    Nasonov, Evgeny L.
    Mysler, Eduardo F.
    da Silva, Nilzio A.
    Alecock, Emma
    Woodworth, Thasia
    Gomez-Rein, Juan J.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (10): : 2968 - 2980
  • [18] Disease-modifying treatment with I2 imidazoline receptor ligand LSL60101 in an Alzheimer's disease mouse model: a comparative study with donepezil
    Vasilopoulou, Foteini
    Rodriguez-Arevalo, Sergio
    Bagan, Andrea
    Escolano, Carmen
    Grinan-Ferre, Christian
    Pallas, Merce
    BRITISH JOURNAL OF PHARMACOLOGY, 2021, 178 (15) : 3017 - 3033
  • [19] Survival of disease-modifying antirheumatic drugs used as the first antirheumatic medication in the treatment of ankylosing spondylitis in Finland. A nationwide population-based register study
    Heikki Relas
    Hannu Kautiainen
    Kari Puolakka
    Lauri J. Virta
    Marjatta Leirisalo-Repo
    Clinical Rheumatology, 2014, 33 : 1135 - 1138
  • [20] Survival of disease-modifying antirheumatic drugs used as the first antirheumatic medication in the treatment of ankylosing spondylitis in Finland. A nationwide population-based register study
    Relas, Heikki
    Kautiainen, Hannu
    Puolakka, Kari
    Virta, Lauri J.
    Leirisalo-Repo, Marjatta
    CLINICAL RHEUMATOLOGY, 2014, 33 (08) : 1135 - 1138
12345